CLRB · Cellectar Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $11.50M | $26.14M | $28.21M | $19.22M | $17.59M | $10.14M |
| SG&A | $11.48M | $25.64M | $10.75M | $9.59M | $6.54M | $5.15M |
| Total Operating Expenses | $22.98M | $51.78M | $38.96M | $28.81M | $24.13M | $15.29M |
| D&A | $213.6K | $291.7K | $192.4K | $148.4K | - | $141.5K |
| Operating Income | ($22.98M) | ($51.78M) | ($38.96M) | ($28.81M) | ($24.13M) | ($15.29M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | $66.0K | ($60.0K) | ($60.0K) | - | - |
| Net Income | ($21.79M) | ($44.58M) | ($37.98M) | ($28.60M) | ($24.12M) | ($15.09M) |
| EPS - Basic | ($8.35) | ($36.60) | ($93.30) | ($121.50) | ($228.00) | - |
| EPS - Diluted | ($8.35) | ($42.00) | ($93.30) | ($121.50) | ($552.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.20M | $23.29M | $9.56M | $19.87M | $35.70M | $57.17M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.44M | $4.11M | $5.62M | $2.56M | $1.42M | $1.43M |
| Current Assets | $14.04M | $24.25M | $10.45M | $20.53M | $36.57M | $57.94M |
| Total Assets | $14.98M | $25.47M | $12.08M | $21.59M | $37.20M | $58.66M |
| Current Liabilities | $4.75M | $9.39M | $12.94M | $5.53M | $3.99M | $3.56M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $5.06M | $9.80M | $13.43M | $6.08M | $4.16M | $3.86M |
| Stockholders' Equity | $8.54M | $14.29M | ($1.36M) | $15.51M | $33.05M | $54.79M |
| Retained Earnings | ($269.13M) | ($247.34M) | ($134.44M) | ($179.50M) | - | ($126.78M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($23.12M) | ($47.58M) | ($32.38M) | ($25.22M) | ($22.57M) | ($13.93M) |
| Investing Cash Flow | ($5.9K) | ($104.2K) | ($864.0K) | ($226.0K) | ($141.4K) | ($62.4K) |
| Financing Cash Flow | $13.03M | $61.41M | $22.94M | $9.61M | $1.25M | $60.55M |
| CapEx | $5.9K | $104.2K | $864.0K | $226.0K | $141.4K | $62.4K |
| Free Cash Flow | ($23.12M) | ($47.69M) | ($33.24M) | ($25.45M) | ($22.71M) | ($14.00M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 1.06 | 1.07 | 0.88 | 0.89 | 0.94 | 0.93 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -145.5% | -175.0% | -314.5% | -132.5% | -64.8% | -25.7% |
| Return on equity | -255.2% | -311.9% | 2801.0% | -184.4% | -73.0% | -27.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.96 | 2.58 | 0.81 | 3.71 | 9.16 | 16.26 |
| Quick ratio | 2.96 | 2.58 | 0.81 | 3.71 | 9.16 | 16.26 |
| Cash ratio | 2.78 | 2.48 | 0.74 | 3.59 | 8.95 | 16.04 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.75 | 1.78 | -8.90 | 1.39 | 1.13 | 1.07 |
| Liabilities / Assets | 0.34 | 0.38 | 1.11 | 0.28 | 0.11 | 0.07 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 0.9x | 23.4x | - | 23.3x | 118.7x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 55.6% | -32.9% | -35.2% | -19.4% | -57.8% | -7.8% |
| Net income growth (YoY) | 51.1% | -17.4% | -32.8% | -18.6% | -59.8% | -7.1% |
| EPS growth (YoY) | 80.1% | 55.0% | 23.2% | 78.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 51.5% | -43.5% | -30.6% | -12.1% | -62.3% | -19.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -40.3% | - | - | -53.1% | -39.7% | 504.8% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Cellectar Biosciences against the 5 most active filers in the same SIC group.